aid: evommune
name: Evommune
description: 'Evommune, Inc. (Nasdaq: EVMN) is a clinical-stage biopharmaceutical company
  headquartered in Palo Alto, California, discovering and developing therapies that target
  the key drivers of chronic inflammatory disease. Founded in 2020 by the team behind
  Dermira, the company applies a human tissue-based translational approach to immunology
  and is advancing a clinical pipeline that includes EVO756, an oral small-molecule
  MRGPRX2 antagonist in Phase 2b development for chronic spontaneous urticaria and
  migraine prophylaxis, and an IL-18 binding protein fusion program licensed from
  AprilBio. Evommune publishes no developer program, no public API and no machine-readable
  API contract; its public web presence is a WordPress marketing site plus a hosted
  investor-relations portal.'
image: https://www.evommune.com/wp-content/uploads/2023/12/Evommune-blue-logo.svg
url: https://raw.githubusercontent.com/api-evangelist/evommune/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Drug Development
- Clinical Trials
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.evommune.com/
- type: About
  url: https://www.evommune.com/about-us/
- type: Contact
  url: https://www.evommune.com/contact/
- type: PrivacyPolicy
  url: https://www.evommune.com/wp-content/uploads/2023/12/Evommune_privacy-statement_for_website.pdf
- type: TermsOfService
  url: https://www.evommune.com/wp-content/uploads/2023/12/Evommune_privacy-statement_for_website.pdf
- type: InvestorRelations
  url: https://ir.evommune.com/
- type: PressReleases
  url: https://ir.evommune.com/news-events/press-releases
- type: Careers
  url: https://www.evommune.com/job-openings/
- type: LinkedIn
  url: https://www.linkedin.com/company/evommune/
- type: Pipeline
  url: https://www.evommune.com/development-pipeline/
- type: Publications
  url: https://www.evommune.com/publications-posters/
- type: DomainSecurity
  url: security/evommune-domain-security.yml
- type: LLMsTxt
  url: llms/evommune-llms.txt
- type: SecondaryMarket
  url: https://forgeglobal.com/evommune_stock/
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Evommune is a clinical-stage biopharmaceutical company (Nasdaq: EVMN) whose entire
    public surface is a WordPress marketing site and a hosted investor-relations portal —
    there is no developer section, no GitHub organization, no package on any registry, and
    every OpenAPI/GraphQL/MCP/agent-card path probed on both hosts returned 404; the only
    HTTP 200 API-shaped response is the stock WordPress REST API at /wp-json/, which is
    default CMS infrastructure rather than a product Evommune publishes.
  evidence:
  - url: https://www.evommune.com/openapi.json
    status: 404
  - url: https://www.evommune.com/.well-known/agent-card.json
    status: 404
  - url: https://ir.evommune.com/llms.txt
    status: 404
  - url: https://api.github.com/orgs/evommune
    status: 404
  - url: https://www.evommune.com/wp-json/
    status: 200
  checked: '2026-08-12'